Biologicals targeting B-cell subsets or antibody-mediated immune response. A large selection of antibodies targeting B-cell epitopes, proteosomes, or the complement system are available for therapy in a variety of autoimmune diseases, including NMHDs. Our review focuses on rituximab (anti-CD20) and eculizumab (anti-C5). Shown are mechanisms of targeting B-cell pathology in the treatment of autoimmune and inflammatory diseases associated with PID. Monoclonal antibodies and mechanisms of action are highlighted. Adapted from Walter et al.¹⁵